Activin A Receptor Type 1B (ACVR1B)

Activin A Receptor Type 1B (ACVR1B)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">Activin A Receptor Type 1B (ACVR1B)</th>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">SMAD2/3</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">SMAD4</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">FKBP1A</td>
<td>Co-receptor</td>
</tr>
<tr>
<td class="label">BAMBI</td>
<td>Pseudoreceptor</td>
</tr>
<tr>
<td class="label">SARA/SMAD anchor</td>
<td>Anchoring</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Pro-inflammatory → Anti-inflammatory switch</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>GFAP modulation</td>
</tr>
<tr>
<td class="label">T cells</td>
<td>Peripheral immune modulation</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</

Activin A Receptor Type 1B (ACVR1B)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">Activin A Receptor Type 1B (ACVR1B)</th>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">SMAD2/3</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">SMAD4</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">FKBP1A</td>
<td>Co-receptor</td>
</tr>
<tr>
<td class="label">BAMBI</td>
<td>Pseudoreceptor</td>
</tr>
<tr>
<td class="label">SARA/SMAD anchor</td>
<td>Anchoring</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Pro-inflammatory → Anti-inflammatory switch</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>GFAP modulation</td>
</tr>
<tr>
<td class="label">T cells</td>
<td>Peripheral immune modulation</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Primary neurons</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">iPSC-derived neurons</td>
<td>Disease modeling</td>
</tr>
<tr>
<td class="label">Organotypic cultures</td>
<td>Circuit analysis</td>
</tr>
<tr>
<td class="label">Astrocyte-neuron co-culture</td>
<td>Glial interaction</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1995</td>
<td>ACVR1B cloning</td>
</tr>
<tr>
<td class="label">2000</td>
<td>SMAD2/3 connection</td>
</tr>
<tr>
<td class="label">2005</td>
<td>Neuronal expression</td>
</tr>
<tr>
<td class="label">2010</td>
<td>Neuroprotection studies</td>
</tr>
<tr>
<td class="label">2015</td>
<td>GDF11 aging research</td>
</tr>
<tr>
<td class="label">2020</td>
<td>Clinical translation</td>
</tr>
<tr>
<td class="label">2024</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent Type</td>
</tr>
<tr>
<td class="label">Activin A agonists</td>
<td>Recombinant protein</td>
</tr>
<tr>
<td class="label">GDF11 analogs</td>
<td>Modified proteins</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Kinase activators</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV vectors</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Ligands</td>
</tr>
<tr>
<td class="label">ACVR1B (ALK4)</td>
<td>Activin A, GDF11, GDF8</td>
</tr>
<tr>
<td class="label">ACVR1 (ALK2)</td>
<td>BMPs, Activin A</td>
</tr>
<tr>
<td class="label">ACVR2A</td>
<td>Activin A, BMPs</td>
</tr>
<tr>
<td class="label">ACVR2B</td>
<td>Activin A, BMPs, GDFs</td>
</tr>
<tr>
<td class="label">BMPR1A</td>
<td>BMPs</td>
</tr>
<tr>
<td class="label">BMPR1B</td>
<td>BMPs</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Gene Symbol: ACVR1B (also known as ALK4) Chromosomal Location: 12q13.13 Path: /genes/acvr1b

Overview

Activin A Receptor Type 1B (ACVR1B/ALK4) is a type I serine/threonine kinase receptor that plays a critical role in TGF-β/activin signaling pathways. As a key mediator of SMAD2/3-dependent signal transduction, ACVR1B is essential for neuronal differentiation, survival, and synaptic plasticity. The receptor is widely expressed in the central nervous system and has been increasingly recognized for its involvement in neurodegenerative disease pathogenesis.

Gene and Protein Structure

Structural Features

The ACVR1B protein consists of:

• Extracellular domain: N-terminal ligand-binding region with cysteine-rich motifs
• Transmembrane domain: Single-pass transmembrane helix
• Kinase domain: Intracellular serine/threonine kinase domain with GS (glycine-serine) regulatory region
• C-terminal kinase domain: Catalytic region for downstream signaling

Signaling Pathway

ACVR1B functions as a primary receptor for:

• Activin A (INHBA homodimer)
• Activin AB (INHBA/INHBB heterodimer)
• GDF11 (Growth Differentiation Factor 11)
• GDF8 (Myostatin)
• Nodal (during development)

Expression Pattern in the Brain

Regional Distribution

ACVR1B is highly expressed in various brain regions:

Cell-Type Specific Expression

• Neurons: High expression in pyramidal neurons and interneurons
• Astrocytes: Moderate expression, increases in reactive states
• Microglia: Low basal expression, upregulated in neurodegeneration
• Oligodendrocytes: Limited expression, more in precursor cells

Role in Neurodegeneration

Alzheimer's Disease (AD)

In Alzheimer's disease, ACVR1B signaling plays a dual role:

Parkinson's Disease (PD)

ACVR1B in Parkinson's disease is particularly relevant to:

Amyotrophic Lateral Sclerosis (ALS)

In ALS, ACVR1B signaling is implicated in:

Frontotemporal Dementia (FTD)

ACVR1B dysregulation has been observed in FTD, particularly:

Molecular Mechanisms

Pro-Survival Signaling

ACVR1B activation triggers several neuroprotective pathways:

Ligand (Activin A/GDF11) → ACVR1B → SMAD2/3 → SMAD4 → Nuclear Translocation
↓
Gene Regulation:

• Bcl-2 family proteins
• Growth factors
• Anti-oxidant enzymes
• Synaptic proteins

Key Downstream Effects

Interactions with Other Proteins

Therapeutic Implications

Targeting ACVR1B in Neurodegeneration

Modulating ACVR1B signaling represents a therapeutic strategy:

Challenges

• Bidirectional effects: Too much or too little signaling can be harmful
• Blood-brain barrier: Delivery challenges for biologics
• Cell-type specificity: Need to target specific populations
• Temporal considerations: Timing of intervention matters

Preclinical Evidence

• GDF11 improves neurogenesis and cognitive function in aged mice
• Activin A protects against Aβ toxicity in neuron cultures
• AAV-mediated ACVR1B delivery shows neuroprotection in PD models

Genetics and Variants

Disease Associations

While ACVR1B is not a major causative gene for familial neurodegenerative diseases, polymorphisms may influence:

• Age of onset
• Disease progression
• Treatment response

Research Status

GWAS studies continue to explore ACVR1B variants in neurodegeneration.

Summary

ACVR1B (ALK4) is a critical receptor for TGF-β/activin signaling in the brain, with established roles in neuronal survival, neurogenesis, and synaptic plasticity. Dysregulation of this pathway contributes to multiple neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and FTD. The receptor's neuroprotective properties make it an attractive therapeutic target, though delivery and specificity challenges remain. Further research on ACVR1B modulators may yield disease-modifying treatments for neurodegeneration.

Pathophysiology in Detail

Cellular Stress Responses

ACVR1B signaling mediates cellular responses to various stressors relevant to neurodegeneration:

Oxidative Stress

The ACVR1B/SMAD2/3 pathway activates antioxidant gene expression:

• SOD2: Manganese superoxide dismutase
• Catalase: Hydrogen peroxide detoxification
• HO-1: Heme oxygenase-1, cytoprotective
• NQO1: NAD(P)H quinone dehydrogenase 1

Mitochondrial Dysfunction

ACVR1B signaling intersects with mitochondrial quality control:

• PGC-1α interaction: Co-activation of mitochondrial biogenesis
• Fusion/fission regulation: Modulates mitochondrial dynamics
• Apoptosis prevention: Bcl-2 family protein regulation

ER Stress

The unfolded protein response (UPR) intersects with ACVR1B signaling:

• XBP1 splicing downstream of ACVR1B
• CHOP regulation influences pro-apoptotic signaling
• ATF6 crosstalk with SMAD pathways

Protein Aggregation Mechanisms

ACVR1B signaling influences protein aggregation in several ways:

Neuroinflammation

ACVR1B has complex immunomodulatory functions:

Signaling Network Analysis

Canonical SMAD Pathway

Non-Canonical Pathways

ACVR1B also signals through non-SMAD pathways:

Experimental Models

In Vitro Models

In Vivo Models

Key Experimental Findings

• GDF11 rejuvenation: Reverses age-related cognitive decline
• Activin A protection: Prevents 6-OHDA toxicity in PD models
• Conditional knockout: SMAD2/3 deletion worsens pathology
• AAV delivery: Improves motor function in PD models

Biomarker Potential

ACVR1B as a Biomarker

Potential clinical applications:

Fluid Biomarkers

• Cerebrospinal fluid: ACVR1B levels measurable
• Blood: Peripheral blood monocyte ACVR1B
• Exosomes: Neuron-derived exosome ACVR1B

Research Timeline

Historical Perspective

Clinical Implications

Diagnostic Applications

Therapeutic Strategies

Pharmacological Approaches

Cell-Based Therapies

• Stem cell delivery: Neurons expressing ACVR1B
• Exosome therapy: ACVR1B-containing exosomes
• Gene editing: CRISPR-based modulation

Clinical Trials

Current status:

• Activin A trials: Planning for AD
• GDF11 trials: Safety studies in progress
• Gene therapy: Preclinical for PD

Comparison with Related Receptors

Receptor Family

Functional Distinctions

• ACVR1B vs ACVR1: More specific to activin signaling
• ACVR1B vs BMPR1A: Different ligand specificity
• ACVR1B vs ACVR2A/B: Different tissue distribution

Future Directions

Research Priorities

Emerging Questions

• How does ACVR1B vary across disease stages?
• Can we develop cell-type specific modulators?
• What determines response to ACVR1B-based therapies?
• How does ACVR1B interact with other therapeutic targets?

References

See Also

• [TGF-β/BMP Signaling Pathway](/mechanisms/tgf-beta-bmp-signaling-pathway)
• [GDF Signaling in Neurodegeneration](/mechanisms/gdf-signaling-neurodegeneration)
• [GDF15/GDF11 in Neurodegeneration](/mechanisms/gdf15-gdf11-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS) - Diseases](/diseases/amyotrophic-lateral-sclerosis)
• [SMAD Signaling Pathway](/mechanisms/smad-signaling-pathway)
• [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling-pathway)